Avelumab (anti–PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: phase 1b results from JAVELIN Lung 101 Alice T. Shaw, 1 Se-Hoon Lee, 2 Suresh S. Ramalingham, 3 Todd M. Bauer, 4 Michael J. Boyer, 5 Enric Carcereny Costa, 6 Enriqueta Felip, 7 Ji-Youn Han, 8 Toyoaki Hida, 9 Brett G. M. Hughes, 10 Sang-We Kim, 11 Makoto Nishio, 12 Takashi Seto, 13 Patrick I. Ezeh, 14 Debasis Chakrabarti, 15 Jing Wang, 16 Andrew Chang, 16 Luca Fumagalli, 17 Benjamin J. Solomon 18 1 Alice T. Shaw, MD, PhD 1 Massachusetts General Hospital Cancer Center, Boston, MA, USA; 2 Samsung Medical Center, Seoul, South Korea; 3 Winship Cancer Institute, Emory University, Atlanta, GA, USA; 4 Tennessee Oncology, Nashville, TN, USA; 5 Chris O'Brien Lifehouse, Camperdown, NSW, Australia; 6 Institut Catala d'Oncologia de Badalona, Servicio de Oncologia Medica, Badalona, Spain; 7 Hospital Universitari Vall d'Hebron, Barcelona, Spain; 8 Center for Lung Cancer, National Cancer Center, Goyang-si, South Korea; 9 Aichi Cancer Center Central Hospital, Nagoya, Japan; 10 The Prince Charles Hospital, Cancer Care Services, Chermside, QLD, Australia; 11 Asan Medical Center, Seoul, South Korea; 12 The Cancer Institute Hospital of JFCR, Tokyo, Japan; 13 National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; 14 Pfizer Inc, Cambridge, MA, USA; 15 Pfizer Inc, Collegeville, PA, USA; 16 Pfizer Inc, San Diego, CA, USA; 17 Pfizer Inc, Milan, Italy; 18 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia Abstract No. 9008
17
Embed
Avelumab (anti PD-L1) in combination with crizotinib or ... · Avelumab (anti–PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC:
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Avelumab (anti–PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: phase 1b results from JAVELIN Lung 101Alice T. Shaw,1 Se-Hoon Lee,2 Suresh S. Ramalingham,3 Todd M. Bauer,4 Michael J. Boyer,5
Enric Carcereny Costa,6 Enriqueta Felip,7 Ji-Youn Han,8 Toyoaki Hida,9 Brett G. M. Hughes,10
Sang-We Kim,11 Makoto Nishio,12 Takashi Seto,13 Patrick I. Ezeh,14 Debasis Chakrabarti,15
Jing Wang,16 Andrew Chang,16 Luca Fumagalli,17 Benjamin J. Solomon18
1Alice T. Shaw, MD, PhD
1Massachusetts General Hospital Cancer Center, Boston, MA, USA; 2Samsung Medical Center, Seoul, South Korea; 3Winship Cancer Institute, Emory University, Atlanta, GA, USA; 4Tennessee Oncology, Nashville, TN, USA; 5Chris O'Brien Lifehouse, Camperdown, NSW, Australia; 6Institut Catalad'Oncologia de Badalona, Servicio de Oncologia Medica, Badalona, Spain; 7Hospital Universitari Vall d'Hebron, Barcelona, Spain; 8Center for Lung Cancer, National Cancer Center, Goyang-si, South Korea; 9Aichi Cancer Center Central Hospital, Nagoya, Japan; 10The Prince Charles Hospital, Cancer Care Services, Chermside, QLD, Australia; 11Asan Medical Center, Seoul, South Korea; 12The Cancer Institute Hospital of JFCR, Tokyo, Japan; 13National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; 14Pfizer Inc, Cambridge, MA, USA; 15Pfizer Inc, Collegeville, PA, USA; 16Pfizer Inc, San Diego, CA, USA; 17Pfizer Inc, Milan, Italy; 18Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
Abstract No. 9008
Disclosures
I have the following financial relationships to disclose:
– Research funding or other research support: Pfizer, Novartis, and Roche/Genentech
– Honoraria: Foundation Medicine, Guardant, Pfizer, Novartis, and Roche/Genentech
2Alice T. Shaw, MD, PhD
Background
• ALK tyrosine kinase inhibitors (TKIs) are standard of care for patients with advanced ALK+ NSCLC1
– Patients can have intrinsic resistance or develop acquired resistance to ALK TKIs
– ALK mutations are responsible for 20% to 25% of cases of crizotinib resistance and approximately 50% of cases of resistance to 2nd-generation ALK TKIs2
– Lorlatinib is a 3rd-generation, CNS–penetrant ALK TKI with potent activity against ALK resistance mutations3
• Checkpoint inhibitors (CPIs) have clinical activity in metastatic NSCLC and prolong overall survival1
– Across multiple clinical trials, CPIs have shown minimal benefit in never-smoking patients4,5
– Retrospective studies have shown minimal activity of CPIs in never-smoking patients, including those with ALK+ NSCLC6
– In the phase 2 ATLANTIC study of durvalumab, no responses were observed among 15 patients with ALK+ NSCLC7
3Alice T. Shaw, MD, PhD
1. NCCN Clinical Practice Guidelines in Oncology. NSCLC V3.2018; 2. Gainor JF, et al. Cancer Discov. 2016; 6:1118-33; 3. Shaw AT, et al. Lancet Oncol. 2017;18:1590-9; 4. Borghaei H,
et al. N Engl J Med. 2015;373:1627-39; 5. Reck M, et al. N Engl J Med. 2016;375:1823-33; 6. Gainor JF, et al. Clin Cancer Res. 2016;22:4584-93; 7. Garassino MC, et al. Lancet Oncol.
2018;19:521-36.
Avelumab
• Avelumab is a human anti–PD-L1 IgG1 antibody with a
wild-type Fc region1
• Preclinical studies suggest that avelumab can
induce antitumor activity by activating both
adaptive and innate immune effector cells2,3
• Avelumab has been approved in various countries
for the treatment of metastatic Merkel cell carcinoma
and in the United States and Canada for advanced urothelial
carcinoma progressing after platinum-based chemotherapy4
• Avelumab has shown antitumor activity and manageable safety in
various other tumors, including single-agent activity in NSCLC5–8
4
T-cell–mediated
immune response
Innate
effector
function
1. Heery CR, et al. Lancet Oncol. 2017;18:587-98; 2. Boyerinas B, et al. Cancer Immunol Res. 2015;3:1148-57; 3. Vandeveer AJ, et al. Cancer Immunol Res. 2016;4:452-62; 4. Bavencio
(avelumab) prescribing information. Rockland, MA, USA: EMD Serono, Inc.; October 2017; 5. Gulley JL, et al. Lancet Oncol. 2017;18:599-610; 6. Choueiri TK, et al. Lancet Oncol.
2018;19: 451-60; 7. Chin K, et al. Ann Oncol. 2017;28:1658-66; 8. Kelly K, et al. Cancer. 2018 Feb 22 (Epub ahead of print).
Alice T. Shaw, MD, PhD
Immune
mediators
Avelumab
PD-1
PD-L1
FcγR
Role of ALK in modulating the immune response
5Alice T. Shaw, MD, PhD
PCR, polymerase chain reaction; shRNA, short hairpin RNA
Figures taken from Zhou P, et al. Nature. 2014;506:52-57.
A B
* p≤.05; ** p≤.01.
Hypotheses for combination treatment
6Alice T. Shaw, MD, PhD
• ALK inhibitors and checkpoint inhibitors may have synergistic activity in non–ALK-driven NSCLC
• Combining ALK inhibitors and checkpoint inhibitors may lead to enhanced efficacy in previously treated ALK+ NSCLC
Avelumab + crizotinib
Avelumab + lorlatinib
Study design: JAVELIN Lung 101Phase 1b/2, open-label, multicenter, dose-finding trial
Key eligibility criteria
Group A
• ALK-negative NSCLC
• No known ROS1 gene rearrangement, c-MET gene
amplification, or c-MET exon 14 skipping
• ≥1 prior regimen of systemic therapy
• No prior antibody/drug targeting a T-cell
coregulatory protein (eg, anti-PD-1/PD-L1)
Group B
• ALK-positive NSCLC
• Any number of prior regimens, including zero
• No prior antibody/drug targeting a T-cell
coregulatory protein (eg, anti-PD-1/PD-L1)
• Asymptomatic untreated brain metastases allowed
7
Initial dose level
Group A
Avelumab 10 mg/kg
(1h IV) Q2W
+ crizotinib
250 mg PO BID
Group B
Avelumab 10 mg/kg
(1h IV) Q2W
+ lorlatinib
100 mg PO QD
Key assessments
Maximum tolerated
dose (MTD) and
recommended
phase 2 dose
Dose-limiting
toxicities
Safety and tolerability
Antitumor activity
Alice T. Shaw, MD, PhD
Data cutoff, October 27, 2017.BID, twice a day; IV, intravenous; PO, by mouth; Q2W, every 2 weeks
• 6/11 evaluable patients (54.5%) had a reduction in tumor size
• 3/11 (27.3%) had tumor shrinkage ≥30%
Avelumab + crizotinib (ALK−): change in target lesions over time
13Alice T. Shaw, MD, PhD
Avelumab + lorlatinib (ALK+): tumor responses
14Alice T. Shaw, MD, PhD
n=28
Confirmed best overall response, n (%)
Complete response
Partial response
Stable disease
Progressive disease
Not evaluable
1 (3.6)
12 (42.9)
6 (21.4)
7 (25.0)
2 (7.1)
Objective response rate, %
(95% CI)
46.4
(27.5–66.1)
Median time to response, months
(range)
1.9
(1.4-3.7)
Median duration of response, months
(95% CI)
7.4
(3.7–NE)
Disease control rate, %
(95% CI)
67.9
(47.6–84.1)
Change in target lesions from baseline
• 16/25 evaluable patients (64.0%) had a reduction in tumor size
• 13/25 (52.0%) had tumor shrinkage ≥30%
Avelumab + lorlatinib (ALK+): responses over time
15Alice T. Shaw, MD, PhD
Time to and duration of response Change in target lesions over time
Conclusions
• Avelumab + lorlatinib treatment in heavily pretreated patients with ALK+ NSCLC showed an acceptable safety profile, with no DLTs
– Antitumor activity was promising, including an ORR of 46% consistent with a prior study of lorlatinib alone1
– Median duration of response was 7.4 months; however, the 95% CI is wide (3.7–not estimable) because the data are still maturing and the number of patients is small
– This arm is currently enrolling treatment-naive, ALK+ NSCLC patients
• Avelumab + crizotinib treatment was not well tolerated, and no further development of this combination is planned
16Alice T. Shaw, MD, PhD
1. Shaw AT, et al. Lancet Oncol. 2017;18:1590-9
Acknowledgments• The authors would like to thank the patients and their families
• The authors would also like to thank the investigators, coinvestigators, and study teams at each of the participating centers and at Pfizer, Inc, New York, NY, USA
• Participating centers:
• This trial was sponsored by Pfizer and is part of an alliance between Merck KGaA, Darmstadt, Germany, and Pfizer
• Medical writing support was provided by ClinicalThinking and was funded by Merck KGaA and Pfizer